Actavis, Warner Chilcott face initial July 10 deadline for antitrust decision
Pharmaceutical company Actavis and rival Nasdaq-listed Warner Chilcott have filed for antitrust approval for their planned $8.5 billion tie-up, according to a statement filed with the US Securities and Exchange Commission.Pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article